www.otsuka-us.com/news/otsuka-... #NephSky #IgANephropathy #IgAN
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT® (sibeprenlimab-szsi) sta...
otsuka-us.com